Liver-Resident NK Cells: The Human Factor by Male, V
  
Liver-Resident NK Cells: the Human Factor 
 
Victoria Male (corresponding author) 
 
Institute of Immunity and Transplantation 
UCL Medical School 
Rowland Hill Street 
London NW3 2PF 
 




Mouse liver contains two NK cell populations, one of which recirculates while the other is 
tissue-resident. Following this discovery, a number of groups have sought to identify liver-




NK cells represent only a small fraction of circulating lymphocytes but account for up to 50% 
of the lymphocytes in the liver. Bulk liver NK cells have long been known to differ from their 
circulating counterparts, but only over the last five years has it become appreciated that the 
liver in fact contains two NK cell subsets: conventional NK cells (cNK) that circulate freely 
and liver-resident NK cells (lrNK). 
 
The Discovery of lrNK in Mice 
NK cells were identified in rodent liver in the mid-1970s, at roughly the same time as their 
discovery in the spleen. A flurry of research on splenic NK cells followed immediately, but 
little work was done on liver NK cells until the early years of this century. In a 2012 study that 
reignited interest in the topic, Gordon and colleagues observed a large population of 
“immature” NK cells in mouse liver, in addition to “mature” cNK [1]. On adoptive transfer, the 
“immature” NK cells could differentiate to cells with a “mature” phenotype. Therefore, they 
proposed that the two NK cell populations in the liver had a precursor-product relationship. 
Daussy and colleagues later repeated the adoptive transfers under more stringent 
conditions, providing evidence that the two populations in fact represent separate lineages 
[2]. Parabiosis experiments showed that one population (cNK) depends on the transcription 
factor Eomes and circulates freely while the other is Tbet-dependent, found in liver sinusoids 
and is unable to leave the liver (lrNK) [3,4]. Further interest in lrNK has been sparked by 
evidence that they can mediate contact hypersensitivity, and could therefore represent 
“memory” NK cells [3]. 
 
The Hunt for lrNK in Humans 
In the light of these findings, a number of groups attempted to define lrNK in humans. CD49a 
is considered the definitive cell surface marker for lrNK in mice, so the first such attempt 
examined the expression of CD49a by human liver NK cells [5]. A small CD49a+ NK cell 
population was found in the parenchyma and these cells are absent in peripheral, portal 
venous or hepatic venous blood, suggesting they are liver-resident.  
 
NK cells in human blood are divided into CD56bright and CD56dim subsets, where the majority 
are CD56dim. Human liver is enriched in CD56bright NK cells and these express CD69, which 
is now recognised as a marker not only of activation but also of tissue residence. Therefore, 
the next attempt at defining lrNK in humans focussed on CD56bright NK cells, finding that they 
express a distinctive panel of chemokine receptors, integrins and L-selectin, which is likely to 
mediate their retention in the liver [6]. Like mouse lrNK, they are located primarily in the 
sinusoids and are likely to be retained there by the interaction of CCR5 and CXCR6, 
expressed by the NK cells, and their ligands on sinusoidal endothelial cells [6]. Indeed, 
  
another recent study has suggested that human lrNK should be defined not as CD56bright but 
as CXCR6+, similar to mouse lrNK [7]. 
 
Neither CD56 nor CXCR6 expression define liver-residence, since significant CD56bright and 
CXCR6+ populations are present in blood [6,7]. A consensus is now emerging that the best 
way to distinguish between cNK and lrNK in humans is by their expression of Tbet and 
Eomes [7-9]. EomeshiTbetlo NK cells (henceforth “Eomeshi”) account for some 50% of human 
liver NK cells, but are completely absent in blood, and largely, but not completely, overlap 
with the CD56bright and CXCR6+ populations. However, the Eomeshi population does not 
overlap with the CD49a+ population [5,7]. It seems, then, that there are two non-overlapping 
NK cell populations that are potentially liver-resident in humans: CD49a+ NK cells and 
Eomeshi (largely CD56bright and CXCR6+) NK cells. 
 
The absence of Eomeshi NK cells in blood, together with their expression of proteins 
associated with tissue retention, points to these cells representing lrNK, but is not definitive. 
Recently, however, we have been able to carry out experiments in humans roughly 
equivalent to the parabiosis experiments that defined lrNK in mice. In clinical liver 
transplantation, donors and recipients are not routinely HLA-matched, allowing recipient-
derived cells to be distinguished from those originating from the donor liver by their 
expression of HLA variants. Taking this approach, we showed that Eomeshi NK cells cannot 
exit the liver and are long-lived in the liver for up to 13 years, whereas Eomeslo cNK cells 
recirculate freely [9]. This allows us to say with some certainty that Eomeshi NK cells are 
indeed liver-resident in humans. 
 
While performing these experiments, we made the unexpected observation that recipient-
derived Eomeshi lrNK emerge within weeks of transplantation, indicating replenishment from 
the circulation. We further found that, on culture with cytokines that are highly expressed in 
the liver, sorted Eomeslo cNK upregulate Eomes together with cell surface markers 
associated with an lrNK phenotype [9]. This was surprising because, in mice, cNK and lrNK 
are thought to form separate lineages [2]. It is, of course, possible that human and mouse 
lrNK differ in this respect but it is worth noting a small degree of flexibility between the two 
lineages in mice, even in the most stringent experiments [2,3]. It is also possible that the 
immunosuppression to which transplant patients are subjected alters the ability of circulating 
cells to be recruited to the liver and fill a resident niche. There is some evidence that this is 
the case for Kupffer cells [10] and it has been suggested that the conflicting outcomes of 
adoptive transfers reported by Gordon and Daussy could be a result of different conditioning 
regimes in the recipient mice. 
 
Future Directions 
In both mice and humans, lrNK cells are present and something of their origin and lineage is 
now understood. However, the function of these cells remains obscure. Since studies in 
humans have been informed by those in mice, experiments in mice are likely to be a 
necessary first step in defining the functions of lrNK in humans. Mouse lrNK may be 
“memory” cells [3] and CD49a+ lrNK in humans are NKG2C+, reminiscent of NKG2C+ NK 
cells in the blood, which may have memory of HCMV [5]. Meanwhile, the longevity of the 
Eomeshi lrNK population could also be suggestive of memory [9]. Experiments to test the 
idea that either population represents memory cells will be challenging to perform in 
humans, although bulk hepatic NK cells in macaques display antigen-specific memory 
responses to vaccination. This supports the notion of memory NK cells in primate liver, 
although the subset responsible has not yet been defined [11].  
 
Anatomical location and protein expression may also provide clues to function. CD49a+ lrNK 
are found in the parenchyma and express cytotoxic effector molecules and receptors for 
MHC class I, so it seems likely that they recognise and kill virally infected or cancerous 
hepatocytes. Eomeshi lrNK, on the other hand, are found in the sinusoids and express fewer 
  
receptors for human targets, suggesting that they may recognise non-human cells in the 
blood. The liver processes blood coming from the gut, so the possibility that they may 
respond to bacteria or bacterial products is particularly attractive. In support of this 
hypothesis, mouse lrNK express high levels of AHR [3,12] while Eomeshi lrNK in humans 
express IL23R and RORγt [9] and these genes are required for the development of ILC3, 
which are involved in the recognition of gut bacteria. Whatever the function of these cells, 
their frequency, longevity and conservation between mice and humans suggests that it is 
likely to be important and defining it will therefore represent a significant advance in our 
understanding of the hepatic immune system. 
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Box 1. Which of the human lrNK populations is equivalent to lrNK in mice? 
CD49a+ human lrNK, like mouse lrNK, express CD49a but differ from them in more respects 
than they are similar, including frequency, anatomical location and expression of receptors 
recognising MHC class I. Therefore it seems likely that these cells are not the human 
equivalents of lrNK in mice. Eomeshi human lrNK also differ from mouse lrNK in a number of 
respects, most strikingly in their expression of Eomes. Although the transcription factor 
dependence of the two subsets in humans in not known, the expression pattern of Eomes 
and Tbet suggests they have exchanged roles between the two species. Given the 
homology of the two transcription factors, and the fact that their roles are often redundant, 
perhaps this should not be too surprising. On the other hand, Eomeshi human lrNK and 
mouse lrNK do correspond in their frequency, location in the sinusoids and expression of a 
number of proteins, such as receptors recognising MHC class I, that are likely to be relevant 
to their function. Therefore, although neither of the two human lrNK populations is precisely 
equivalent to mouse lrNK, the Eomeshi population seems to be the more similar of the two. 
The phenotypic and functional characteristics of cNK and lrNK in both species are 




Table 1. Features of cNK and lrNK in mice and humans. -: not expressed; +: low 
expression/a small fraction of cells are positive; ++: intermediate expression/approximately 
half of cells are positive; +++ high expression/the majority of cells are positive; ND: not 
determined; N/A: not applicable. *: In humans, CD56brightCD16- NK cells are considered less 
mature than CD56dimCD16+ cells; in mice as NK cells mature, they first acquire CD11b 
(integrin αM) and then lose CD27 (a TNFR family molecule). **: KIR family in humans, Ly49 
family in mice. ***: There are conflicting reports of granzyme expression in mouse lrNK. It 
has been reported that granzyme A mRNA does not differ between lrNK and cNK [4], 
whereas another study identified cNK as expressing granzyme A protein, whereas lrNK did 
not [2]. At the protein level, granzyme B has been reported to not differ between lrNK and 














Location Circulating Sinusoidal  Circulating Parenchymal Sinusoidal 
% of total NK in liver N/A ~50%  N/A 0 – 12% ~50% 
 
Cell surface markers 
CD49a (integrin α1) - +  - + - 
CD49b (integrin α2) + -  ND ND ND 
CD69 - +  - + + 
CD127 (IL-7 receptor) - +  - - - 
CXCR6 (chemokine 
receptor) 
- +  - - + 
Maturation markers* ++ +  ++ + + 
MHC-I specific 
receptors** 
++ +  ++ +++ - 
NKG2A/CD94 
(inhibitory NK receptor) 
+ ++  +  - ++ 
NKp46 (activating NK 
receptor) 
+ +  + + + 
 
Transcription factor expression 
Eomes ++ +  + + ++ 
Tbet ++ ++  ++ ++ + 
 
Function 
Perforin ++ +  ++ ++ + 
Granzyme A ++ - or ++***  ++ ++ ND 
Granzyme B ++ - or ++***  ++ ++ + 
Degranulation ++ +  ++ + +++ 
TRAIL - ++  - ND - 
Cytotoxicity ++ +++  ++ ND + 
IFNg ++ ++  ++ + ++ 
TNFa ++ +++  ++ + + 
GM-CSF ++ +++  ++ + ++ 
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